A Study to Evaluate Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

The registered record

Accession number

NCT07327359

Lead sponsor

Olix Pharmaceuticals, Inc. (industry)

Collaborators

Avance Clinical Pty Ltd.

Registered condition naming hair loss

Androgenetic Alopecia (AGA)

Official title

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1b/2a Study to Evaluate the Safety and Efficacy of OLX72021 in Healthy Males With Androgenetic Alopecia

Interventions

• DrugOLX72021
• DrugOLX72021
• DrugOLX72021
• DrugPlacebo

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Phase 1/2

Allocation

randomized

Masking

double

Primary purpose

treatment

Enrolment

158 participants (estimated)

Sites

1 location in Australia

What it measures

1. To investigate the incidence, type, severity, and relationship of adverse events (AEs)/serious AEs (SAEs), assessed using the CTCAE Version 5.0 (Phase 1b)

   Time frame: From baseline to end of study (Day 85)

2. To assess local tolerability at intradermal (ID) injection site (Phase 1b)

   Time frame: From baseline to end of study (Day 85)

3. To evaluate the change from baseline in non-vellus Target Area Hair Count (TAHC) at 24 weeks (Day 169) (Phase 2a)

   Time frame: Baseline to Day 169

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

male

Age

18 Years to 59 Years

Healthy volunteers

accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

4 December 2025 (actual)

Primary completion

April 2026 (estimated)

Study completion

March 2027 (estimated)

First posted

8 January 2026 (actual)

Last update posted

6 March 2026 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2026-04 is a month, and rendering it as 1 April 2026 would invent a day the sponsor did not register.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Androgenetic Alopecia: Complete GuideNew Hair Loss Treatments in Clinical Trials: Clascoterone, Pyrilutamide and What the Published Data Actually ShowComplete Guide to Finasteride for Hair LossMinoxidil 5% Complete Guide: How to Apply for Best Results

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT07327359 on ClinicalTrials.gov · All 157 trials in the pipeline